Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan H Rayment

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Pediatric Pulmonology|July 11, 2025
Repeatability of Multiple Breath Washout in Pediatric Primary Ciliary DyskinesiaWallace B Wee, Layan M Bashi, Renee Jensen, et al.
ERJ Open Research|March 18, 2026
Utility of hyperpolarised xenon-129 magnetic resonance imaging in primary ciliary dyskinesiaWallace B Wee, Brandon Zanette, Samal Munidasa, et al.
Annals of the American Thoracic Society|June 29, 2022
Heterogenous Disease Course and Long-Term Outcome of Children's Interstitial Lung Disease Related to Filamin A Gene VariantsJulia Carlens, K Taneille Johnson, Andrew Bush, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2022
A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for <i>F508del-CFTR</i>Jonathan H Rayment, Fadi Asfour, Margaret Rosenfeld, et al.
Thorax|December 9, 2025
Heterogeneity of short-term elexacaftor-tezacaftor-ivacaftor response in cystic fibrosis using <sup>129</sup>Xe MRIRachel L Eddy, Vanessa M Diamond, Josie Chrenek, et al.
Radiology. Cardiothoracic Imaging|August 7, 2025
Hyperpolarized <sup>129</sup>Xe MRI and Spectroscopy: Quantitative Measurements, Results, and Emerging OpportunitiesAlexandra Schmidt, James A Liggins, Haad Bhutta, et al.
Respiratory Medicine|April 22, 2026
Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor on Health-Related Quality of Life in Adults with Cystic Fibrosis: A 12-Month Multicenter Cohort StudyRazan Kharraz, Elizabeth Tullis, Jenna Sykes, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 9, 2020
Factors influencing clinical trial participation for adult and pediatric patients with cystic fibrosisMarissa Lee, Xun Yang Hu, Sameer Desai, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 18, 2026
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension studyJennifer L Goralski, Cori Daines, Jessica E Pittman, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Clinical TrialClaire Wainwright, Susanna A McColley, Paul McNally, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Pediatric Pulmonology|July 11, 2025
Repeatability of Multiple Breath Washout in Pediatric Primary Ciliary DyskinesiaWallace B Wee, Layan M Bashi, Renee Jensen, et al.
ERJ Open Research|March 18, 2026
Utility of hyperpolarised xenon-129 magnetic resonance imaging in primary ciliary dyskinesiaWallace B Wee, Brandon Zanette, Samal Munidasa, et al.
Annals of the American Thoracic Society|June 29, 2022
Heterogenous Disease Course and Long-Term Outcome of Children's Interstitial Lung Disease Related to Filamin A Gene VariantsJulia Carlens, K Taneille Johnson, Andrew Bush, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2022
A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for <i>F508del-CFTR</i>Jonathan H Rayment, Fadi Asfour, Margaret Rosenfeld, et al.
Thorax|December 9, 2025
Heterogeneity of short-term elexacaftor-tezacaftor-ivacaftor response in cystic fibrosis using <sup>129</sup>Xe MRIRachel L Eddy, Vanessa M Diamond, Josie Chrenek, et al.
Radiology. Cardiothoracic Imaging|August 7, 2025
Hyperpolarized <sup>129</sup>Xe MRI and Spectroscopy: Quantitative Measurements, Results, and Emerging OpportunitiesAlexandra Schmidt, James A Liggins, Haad Bhutta, et al.
Respiratory Medicine|April 22, 2026
Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor on Health-Related Quality of Life in Adults with Cystic Fibrosis: A 12-Month Multicenter Cohort StudyRazan Kharraz, Elizabeth Tullis, Jenna Sykes, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 9, 2020
Factors influencing clinical trial participation for adult and pediatric patients with cystic fibrosisMarissa Lee, Xun Yang Hu, Sameer Desai, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 18, 2026
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension studyJennifer L Goralski, Cori Daines, Jessica E Pittman, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Clinical TrialClaire Wainwright, Susanna A McColley, Paul McNally, et al.
Pageof 7